Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients

Gynecological Endocrinology

Volumn 28, Issue 9, 2012, Pages 740-745

  Pup, Lino Del ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Dyspareunia; Female cancer patients; Promestriene; Vaginal dryness; Vaginal estrogens

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; FOLLITROPIN; LUBRICATING AGENT; PROMESTRIENE;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVOR; CIRCULATION; COITUS; COLPOSCOPY; CREAM; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DYSPAREUNIA; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GEL; HAZARD RATIO; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SMOKING CESSATION; UROGENITAL TRACT DISEASE; UTERINE CERVIX CANCER; UTERUS BLEEDING; VAGINA MUCOSA; VAGINAL DRYNESS; VAGINISM;

ADMINISTRATION, INTRAVAGINAL; DYSPAREUNIA; ESTROGENS; FEMALE; HUMANS; LUBRICANTS; LUBRICATION; NEOPLASMS; VAGINA; VAGINAL DISEASES;

EID: 84865341359     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.652717     Document Type: Article

References (68)

1. Schover L R. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008; 26: 753-758 (Pubitemid 351264388)
2. Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol 2006;17:1777-1782. (Pubitemid 44884052)
3. Santos I, Clissold S. Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy. Gynecol Endocrinol 2010;26:644-651.
4. Ewies AA, Alfhaily F. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? Climacteric 2010;13:405-418.
5. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194-203.
6. Stenberg A, Heimer G, Ulmsten U. The prevalence of urogenital symptoms in postmenopausal women. Maturitas 1995;22(Suppl):S17-20 (Pubitemid 26021027)
7. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501-514. (Pubitemid 28135592)
8. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-2744.
9. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365-2370. (Pubitemid 29368234)
10. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsa9 Group. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-284. (Pubitemid 44707921)
11. Harris PF, Remington PL, Trentham-Dietz A, Allen CI, Newcomb PA. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002;23:501-509. (Pubitemid 34627035)
12. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983;249:2195-2198. (Pubitemid 13118676)
13. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;92:1054-1064. (Pubitemid 30618024)
14. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-263. (Pubitemid 26000605)
15. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994;61:178-180. (Pubitemid 24030700)
16. Del Pup L. How to treat vaginal atrophy and dyspareunia in oncological patients? Abstract from 13° World Congress on Human Reproduction, Venice 2009.
17. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997;15:969-973. (Pubitemid 27106279)
18. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727. (Pubitemid 28440818)
19. Palacios S, Castelo-Branco C, Cancelo MJ, Vá zquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005; 50: 98-104. (Pubitemid 40094756)
20. Suckling JA, Kennedy R, Lethaby A, Roberts H Local oestrogen for vaginal atrophy in postmenopausal women (Review) Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001500
21. Ponzone R, Biglia N, Jacomuzzi ME, Maggiorotto F, Mariani L, Sismondi P. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 2005;41:2673-2681. (Pubitemid 41607558)
22. Trinkaus M, Chin S, Wolfman W, Simmons C, Clemons M. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222-231. (Pubitemid 351679897)
23. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies, J Natl Cancer Inst 2002; 94: 606-616
24. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 2000;73:292-299. (Pubitemid 30060362)
25. Ganz PA, Greendale G, Kahn B, O'Leary JF. Are breast cancer survivors willing to take hormone replacement therapy (HRT) (abstract A102). Proceedings of the Annual Meeting of Society Clinical Oncology 1996:15
26. Wolff JP, Cachelou R, Guéritée N. Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa. Maturitas 1982;4:239-246. (Pubitemid 13189092)
27. Del Pup L. Safety and tolerance of promestriene and its use in oncology patients. Abstract 8Th European Congress on Menopause (EMAS), London, 2009.
28. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52. (Pubitemid 36398872)
29. Rosenberg LU, Magnusson C, Lindström E, Wedrén S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.
30. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762. (Pubitemid 32514798)
31. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006;17:584-587.
32. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-1802. (Pubitemid 37362955)
33. Rigg LA, Hermann H, Yen SS. Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-197. (Pubitemid 8272278)
34. Pschera H, Hjerpe A, Carlström K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989;27:204-207. (Pubitemid 19134308)
35. Fraser IS, Wang Y. New delivery systems for hormone replacement therapy. In Wren BG, ed. Progress in the Management of the Menopause. Carnforth, UK: Parthenon Publishing, 1997: 58-67
36. Nash HA, Brache V, Alvarez-Sanchez F, Jackanicz TM, Harmon TM. Estradiol delivery by vaginal rings: potential for hormone replacement therapy. Maturitas 1997;26:27-33. (Pubitemid 27063778)
37. Toniolo P, Lukanova A. The challenge of measuring circulating estradiol at low concentrations. Breast Cancer Res 2005;7:45-47. (Pubitemid 40352668)
38. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005;7:1-4. (Pubitemid 40214529)
39. Jones ME, Folkerd EJ, Doody DA, Iqbal J, Dowsett M, Ashworth A, Swerdlow AJ. Effect of delays in processing blood samples on measured endogenous plasma sex hormone levels in women. Cancer Epidemiol Biomarkers Prev 2007;16:1136-1139. (Pubitemid 46984949)
40. Englund DE, Johansson ED. Plasma levels of oestrone, oestradiol and gonadotrophins in postmenopausal women after oral and vaginal administration of conjugated equine oestrogens (Premarin). Br J Obstet Gynaecol 1978;85:957-964. (Pubitemid 9030437)
41. Furuhjelm M, Karlgren E, Carlström K. Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int J Gynaecol Obstet 1980;17:335-339.
42. Adams WP, Hasegawa J, Johnson RN, Haring RC. Conjugated estrogens bioinequivalence: comparison of four products in postmenopausal women. J Pharm Sci 1979;68:986-991. (Pubitemid 9242703)
43. van der Linden MC, Gerretsen G, Brandhorst MS, Ooms EC, Kremer CM, Doesburg WH. The effect of estriol on the cytology of urethra and vagina in postmenopausal women with genito-urinary symptoms. Eur J Obstet Gynecol Reprod Biol 1993;51:29-33. (Pubitemid 23340889)
44. Heimer GM. Estriol in the postmenopause. Acta Obstet Gynecol Scand Suppl 1987;139:1-23.
45. Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, Marci R, Cosmi E. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. Menopause 2004;11:49-56. (Pubitemid 40362198)
46. Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 1995;62:101-106.
47. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergström R, Correia N, Persson I. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353: 1824-1828. (Pubitemid 29251013)
48. Mattsson LA, Cullberg G, Eriksson O, Knutsson F. Vaginal administration of low-dose oestradiol-effects on the endometrium and vaginal cytology. Maturitas 1989;11:217-222. (Pubitemid 19249682)
49. Bachmann G. Vulvovaginal complaints. In Lobo R, ed. Treatment of the Postmenopausal Woman. New York: Raven Press, 1994: 137-42
50. Head KA., Estriol: safety and efficacy, Alt Med Rev 1998;3: 101-113 (Pubitemid 128709606)
51. Bottiglione F, Volpe A, Esposito G, Aloysio DD. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas 1995;22:227-232.
52. Mattsson LA, Cullberg G. A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand 1983;62:397-401. (Pubitemid 14213524)
53. Manonai J, Theppisai U, Chittacharoen A. Effect and safety of 17 betaestradiol vaginal tablet in postmenopausal women with urogenital symptoms. J Med Assoc Thai 2001;84:1015-1020. (Pubitemid 34076009)
54. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001;27:255-260. (Pubitemid 33121175)
55. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556-562. (Pubitemid 34246288)
56. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92. (Pubitemid 40675125)
57. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 2009;16:30-36.
58. Belaish J, Thomas JL, Becker, Lumbroso M. Esperienza francese ed europea con il promestriene. In: Bottiglioni F. Il cimaterio femminile. Torchio de Ricci 1988: 29-44
59. Borrelli AL, Casolaro AM, Esposito G, Berlingieri D. [Biologic action of promestriene on the genital tract of the castrated rat]. Minerva Ginecol 1990;42:467-472.
60. Kobata SA, Girão MJ, Baracat EC, Kajikawa M, Di Bella V Jr, Sartori MG, Jármy-Di Bella ZI. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis. Maturitas 2008;61:243-247.
61. Del Pup L. Bollettino di Ginecologia Endocrinologica 2010; 4: 68-73
62. ASCUS LSIL Triage Study Group. Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUSLSIL Triage Study (ALTS). Am J Obstet Gynecol 2006;195: 341-8.
63. Flynn K, Rimm DL. Diagnosis of "ASCUS" in women over age 50 is less likely to be associated with dysplasia. Diagn Cytopathol 2001;24:132-136. (Pubitemid 32108523)
64. Dresang LT. Colposcopy: an evidence-based update. J Am Board Fam Pract 2005;18:383-392. (Pubitemid 41663982)
65. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-2390. (Pubitemid 34493201)
66. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCPSponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-2129. (Pubitemid 34437347)
67. Solomon D, Stoler M, Jeronimo J, Khan M, Castle P, Schiffman M. Diagnostic utility of endocervical curettage in women undergoing colposcopy for equivocal or low-grade cytologic abnormalities. Obstet Gynecol 2007;110:288-295. (Pubitemid 47356652)
68. Piccoli R, Mandato VD, Lavitola G, Acunzo G, Bifulco G, Tommaselli GA, Attianese W, Nappi C. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: implications for management. Eur J Obstet Gynecol Reprod Biol 2008;140:269-274.